No medications are currently approved for treating nonmonogenic, nonsyndromic obesity in children under 12 years of age. Although liraglutide has demonstrated weight-loss benefits in adults and adolescents with obesity , its safety and efficacy in younger children have not been well established. To address this gap, a study evaluated the safety and effectiveness of liraglutide for obesity management in 82 children. The study found that at week 56, children receiving liraglutide had a greater reduction in BMI than those receiving placebo (−5.8% vs. +1.6%).
Body weight change was also lower in the liraglutide group (1.6% vs. 10.0%). A reduction in BMI of at least 5% occurred in 46% of participants receiving liraglutide compared with 9% in the placebo group (adjusted OR 6.3). Adverse events occurred in 89% of the liraglutide group and 88% of the placebo group, with gastrointestinal events…
